For the 1.3 million Zimbabweans living with HIV, and for the millions more at risk, the medical landscape shifted in February 2026. Zimbabwe became one of the first countries in the world to roll out lenacapavir, a long-acting injectable form of pre-exposure prophylaxis that requires only two injections per year to provide protection against HIV infection.
The rollout launched in February through 24 sites nationally and targets 46,000 high-risk individuals in its initial phase.
Zimbabwe has spent more than two decades building one of the most extensive HIV response systems in sub-Saharan Africa. Treatment access, community health programmes and sustained donor funding have reduced HIV prevalence dramatically since the early 2000s.
Lenacapavir targets populations at highest risk
The programme focuses on groups whose HIV vulnerability remains significantly higher than the national average.
Priority recipients include sex workers, adolescent girls and young women, men who have sex with men, and pregnant or breastfeeding women.
These groups often face social and economic conditions that make consistent daily medication difficult.
Lenacapavir changes the prevention equation by removing the need for daily pills.
A prevention method that works without daily medication
Traditional pre-exposure prophylaxis, commonly known as PrEP, involves taking a pill every day to maintain protection against HIV infection.
When taken consistently, PrEP is highly effective. Maintaining that consistency, however, has been a major challenge for many people.
For someone managing unstable work schedules, childcare responsibilities or the need for privacy around HIV prevention, keeping a daily medication routine can be difficult.
A twice-yearly injection simplifies the process.
One clinic visit provides six months of protection. No daily medication. No pills to store or conceal.
Public health experts say that shift could significantly increase prevention uptake among people who struggle with adherence to oral PrEP.
Programme funded by international health partners
The lenacapavir rollout is offered free of charge to participants.
Funding comes primarily from the United States government and the Global Fund to Fight AIDS, Tuberculosis and Malaria, long-standing partners in Zimbabwe’s national HIV response.
These organisations have supported antiretroviral treatment expansion, prevention programmes and community outreach initiatives across the country.
Health officials say funding for the initial rollout phase has been secured, although broader uncertainties around international aid programmes remain a factor for long-term planning.
Zimbabwe’s HIV progress sets foundation for new prevention tools
Zimbabwe’s HIV response has achieved major progress over the past two decades.
National HIV prevalence has fallen from roughly 34 percent in the early 2000s to about 12 percent today.
More than 90 percent of people living with HIV are now receiving antiretroviral therapy, a treatment coverage rate that surpasses many higher-income countries.
That treatment infrastructure makes it possible to introduce new prevention technologies like lenacapavir through existing clinics and community health networks.
Public health officials see the injection as a critical addition to existing prevention strategies.
Two injections per year may prove to be one of the most practical tools yet developed to reduce new HIV infections.
Additional reporting sourced from Zimbabwe health programme briefings. The Granite Post has independently verified key details.
